{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/parvovirus-b19-infection/diagnosis/investigations/","result":{"pageContext":{"chapter":{"id":"2b824d0f-b0b0-5801-8def-a38d172c2532","slug":"investigations","fullItemName":"Investigations","depth":2,"htmlHeader":"<!-- begin field 38a42311-61ce-4939-b36c-c856c60e7e3b --><h2>How should I investigate suspected Parvovirus B19 infection?</h2><!-- end field 38a42311-61ce-4939-b36c-c856c60e7e3b -->","summary":"","htmlStringContent":"<!-- begin item 8cdcfe05-a0b4-41f9-b946-b819e200ff2b --><!-- begin field 5b64bb6a-e8f5-47fd-a22a-966fde92e70a --><ul><li><strong>In healthy children and adults, the diagnosis of parvovirus B19 infection should be based on <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/diagnosis/diagnosis/\">clinical features</a>,</strong> and laboratory investigation to confirm the diagnosis is not required. Note: parvovirus B19 infection is not a notifiable disease.</li><li><strong>If a pregnant woman has suspected parvovirus B19 infection, contact the local virology, microbiology, or infectious diseases department immediately for further advice.</strong> This is likely to include urgent blood testing for:<ul><li>Parvovirus B19-specific immunoglobulin M (IgM). Note: serum from antenatal booking bloods or earlier samples may be available to help confirm the diagnosis, but initial blood testing should not be delayed.<ul><li>If parvovirus B19-specific IgM is not detected, this excludes infection in the four weeks prior to the blood test. Infection cannot be excluded if the blood test is taken more than four weeks after the onset of rash or associated illness. Seek specialist advice on any additional testing needed, for example, of antenatal booking bloods.</li></ul></li><li>If parvovirus B19-specific IgM is detected in the first 20 weeks of pregnancy, this suggests recent infection with parvovirus B19, and the diagnosis is confirmed by testing for:<ul><li>High-titre viral DNA using polymerase chain reaction (PCR) analysis, or</li><li>Parvovirus B19-specific IgG in antenatal booking blood samples.</li></ul></li><li>Rubella infection, irrespective of the woman's previous testing or immunization status to rubella. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/rubella/\">Rubella</a> for more information on laboratory tests to arrange and subsequent management.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/management/pregnant-women/#management-of-suspected-infection-in-pregnancy\">How should I manage suspected parvovirus B19 infection in pregnancy?</a> for more information.</li></ul></li><li><strong>If a pregnant woman has had possible exposure to parvovirus B19 infection, contact the local virology, microbiology, or infectious diseases department immediately for further advice.</strong> This is likely to include urgent blood testing for:<ul><li>Parvovirus B19-specific IgG and IgM.</li><li>Rubella infection (if the woman is not known to be immune). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/rubella/\">Rubella</a> for more information on laboratory tests to arrange and subsequent management.</li></ul></li><li>If the parvovirus B19 Ig result is:<ul><li>Positive for IgG and negative for IgM, reassure the woman that she has had past (but not recent) parvovirus B19 infection, and she is immune. Retesting is not necessary.</li><li>Negative for both IgG and IgM, she is susceptible to infection. Repeat a blood test one month after last contact even if she remains asymptomatic (or earlier if symptoms develop). If the repeat test is:<ul><li>Negative for both IgG and IgM, reassure the woman that there is no evidence of recent infection, but she remains susceptible to future infection.</li><li>Positive for IgM and negative for IgG, repeat a blood test immediately. If this result is positive for IgM, this suggests recent infection with parvovirus B19, and the diagnosis is confirmed by testing for high-titre viral DNA using PCR analysis, or parvovirus B19-specific IgG in antenatal booking blood samples.</li></ul></li><li>Positive for IgM (irrespective of the IgG result), this suggests recent infection with parvovirus B19, and the diagnosis is confirmed by testing:<ul><li>An antenatal booking blood sample or</li><li>A repeat blood test after 7–10 days. Seek specialist advice on any additional testing needed.</li></ul></li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/management/pregnant-women/#management-of-possible-exposure-in-pregnancy\">How should I manage possible exposure to parvovirus B19 infection in pregnancy?</a> for more information.</li></ul></li><li><strong>If parvovirus B19 infection is suspected in a person who is immunocompromised, has a haematological disorder, or is in early <a class=\"topic-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/background-information/complications/\">transient aplastic crisis</a>,</strong> arrange urgent blood testing for:<ul><li>High-titre viral DNA using PCR analysis, to confirm the diagnosis of parvovirus B19 infection. Contact the local virology, microbiology, or infectious diseases department if there is any uncertainty about blood tests to arrange.</li><li>Full blood count (including reticulocyte count).</li></ul></li><li><strong>If there is any uncertainty about laboratory investigations to arrange or how to interpret results,</strong> contact the local virology, microbiology, or infectious diseases department for further advice.</li></ul><!-- end field 5b64bb6a-e8f5-47fd-a22a-966fde92e70a --><!-- end item 8cdcfe05-a0b4-41f9-b946-b819e200ff2b -->","topic":{"id":"a0e6adce-f85f-55b0-8d7f-3b5e75836d40","topicId":"3ea4cf87-3eee-4e3f-a6d0-b0ee3a4ee3ad","topicName":"Parvovirus B19 infection","slug":"parvovirus-b19-infection","lastRevised":"Last revised in February 2017","chapters":[{"id":"c45face5-dc30-586a-b7ca-3b24305bd068","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"cc09231e-bb7a-5379-aeec-7c830288098e","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2971cfc1-4839-5be6-b726-20b9383ae294","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"020d2cdb-0f7f-5bc0-a249-98fc3690b68c","slug":"changes","fullItemName":"Changes"},{"id":"af1bc49c-d614-521b-b6f3-ad084fc2aed9","slug":"update","fullItemName":"Update"}]},{"id":"7c9f0c10-cf1d-5723-856f-e0bc2d270210","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bb1635ce-433b-5f39-a93a-27b4488878c5","slug":"goals","fullItemName":"Goals"},{"id":"3c7eed51-287a-5bcb-8519-40ef7f5784aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"291f85a1-8911-59d4-82d6-62ce4daff1c0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e66b8854-eb00-59b9-85d9-f50343f36470","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce817770-4fbe-5b47-b4ed-56b723012488","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"faa5c5db-5837-5cbd-8e56-78bc7ac42137","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0f0e8f26-e2c7-5de3-b012-e340b25ad622","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"afcf1b63-41ac-5295-91b5-4e19bc828249","slug":"definition","fullItemName":"Definition"},{"id":"60a93741-3863-58bb-8394-a33804062373","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1cfa61b6-71af-5e94-9e40-95b29e9f97dc","slug":"complications","fullItemName":"Complications"},{"id":"034c66fb-a99f-5a21-a031-d557dc647301","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"53019719-ec11-57d5-afd3-3ed2e9939168","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"e7eca192-b219-5e71-8ecd-6d2e6cf0f3da","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"2b824d0f-b0b0-5801-8def-a38d172c2532","slug":"investigations","fullItemName":"Investigations"},{"id":"7daba43a-1410-5703-8a94-b6530a5dfccc","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"b0275eae-f19c-57fb-834c-03df7c6dcea3","fullItemName":"Management","slug":"management","subChapters":[{"id":"73c2e9d4-b567-504f-9b28-36966a247590","slug":"children-adults-not-pregnant","fullItemName":"Scenario: Children and adults (not pregnant)"},{"id":"25b4fecb-ae9d-58f7-ad14-7ace595c0800","slug":"pregnant-women","fullItemName":"Scenario: Pregnant women"}]},{"id":"bdf3d270-5563-5eb4-804f-68fce2e7e7dd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"73875656-8429-5584-82e6-d06c0a5f52ea","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8dc117ba-c373-5ee0-a7aa-fc63a62a7067","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"24bd5691-28ce-53b1-be8b-f0e51e40db4b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6b35b969-66a8-5431-900a-a524f0bf1a89","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"63ad51a8-8325-52f2-a254-ed3ccae9f508","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"174a35a7-6fa3-58ef-9e06-6325d5f0111b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c6c0fc6f-31f8-5681-bbce-4ed5b6b16e4e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"53019719-ec11-57d5-afd3-3ed2e9939168","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"f43b08a5-5c0f-5152-a1ab-2c901ef78e2c","slug":"basis-for-recommendation-a4f","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 4cb4b735-8343-4c4f-aebf-e09d6c5b8e28 --><h3>Basis for recommendation</h3><!-- end field 4cb4b735-8343-4c4f-aebf-e09d6c5b8e28 -->","summary":null,"htmlStringContent":"<!-- begin item a4fb4fc5-a269-490a-b4d2-a8fba0ae000c --><!-- begin field 046a952a-43df-4bed-9dbd-199b42d27db6 --><h4>Investigations in healthy children and adults</h4><ul><li>The recommendation that laboratory investigation is not needed in healthy children and adults is based on the fact that parvovirus B19 infection is usually mild and self-limiting in this population group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">UK National Screening Committee, 2014</a>].</li></ul><h4>Investigations in pregnant women</h4><ul><li>The recommendation to seek immediate specialist advice if a pregnant women has suspected parvovirus B19 infection or there has been possible exposure to the virus is extrapolated from expert opinion in a review article on pregnant women exposed to a childhood rash [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">MacMahon, 2012</a>].<ul><li>Testing of stored antenatal booking blood samples may help to clarify the diagnosis by showing immunoglobulin G (IgG) seroconversion, which is useful in asymptomatic infection, or if possible exposure has not been reported for several weeks.</li></ul></li><li>The information on the specific blood tests that are likely to be needed are largely based on expert opinion in the Public Health England (PHE) publications <em>Guidance on viral rash in pregnancy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">HPA, 2011</a>] and <em>UK Standards for microbiology investigations. Investigation of pregnant women exposed to non-vesicular rash</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">PHE, 2015</a>].<ul><li>Serological confirmation of infection in pregnancy is essential as parvovirus B19 can have potentially serious or life-threatening sequelae for the fetus (and more rarely the mother).</li></ul></li></ul><h4>Investigations in people who are immunocompromised or have haematological disorders</h4><ul><li>Serological confirmation of infection in people who are immunocompromised or have haematological disorders is important as these population groups are at increased risk of potentially serious or life-threatening complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">American Association of Blood Banks, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">Slavov, 2011</a>].</li><li>Immunocompromised people and people in early transient aplastic crisis may not produce a detectable antibody response to acute infection (IgM testing may be negative in people with current or recent infection). Additional tests such as polymerase chain reaction (PCR) analysis for detection of high-titre viral DNA may be necessary to confirm the diagnosis. The detection of IgG in previous blood samples may also suggest seroconversion in people who are immunocompromised [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">Slavov, 2011</a>].</li></ul><h4>Seeking specialist advice</h4><ul><li>The recommendation to seek specialist advice if there is any uncertainty about tests to arrange or in the interpretation of results, is extrapolated from expert opinion in a review article on pregnant women exposed to childhood rash [<a class=\"bibliography-reference internal-reference\" href=\"/topics/parvovirus-b19-infection/references/\">MacMahon, 2012</a>].</li></ul><!-- end field 046a952a-43df-4bed-9dbd-199b42d27db6 --><!-- end item a4fb4fc5-a269-490a-b4d2-a8fba0ae000c -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}